Immunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of “Buy” from Brokerages

Immunic, Inc. (NASDAQ:IMUX) has been assigned a consensus recommendation of “Buy” from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $12.67.

IMUX has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Immunic in a research note on Friday, February 21st. William Blair initiated coverage on shares of Immunic in a report on Tuesday. They set an “outperform” rating on the stock. D. Boral Capital reissued a “buy” rating and issued a $17.00 price target on shares of Immunic in a research note on Wednesday, February 26th. Finally, StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research report on Thursday, March 20th.

Immunic Trading Up 3.3 %

Shares of Immunic stock opened at $1.24 on Friday. The firm has a market capitalization of $111.70 million, a PE ratio of -1.01 and a beta of 1.89. Immunic has a 12 month low of $0.92 and a 12 month high of $2.11. The business’s 50-day moving average price is $1.08 and its 200-day moving average price is $1.21.

Hedge Funds Weigh In On Immunic

A number of hedge funds have recently modified their holdings of IMUX. Jane Street Group LLC grew its stake in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the last quarter. HB Wealth Management LLC purchased a new stake in Immunic in the 4th quarter worth approximately $81,000. State Street Corp grew its position in shares of Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after buying an additional 11,642 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after buying an additional 42,383 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Immunic during the third quarter valued at approximately $50,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.